Lv4
705 积分 2021-03-22 加入
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): f inal prespecified overall survival results of a randomised, double-blind, phase 3 trial
11小时前
待确认
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer
11小时前
已完结
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
12小时前
已完结
FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
12小时前
已完结
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
1天前
已完结
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
8天前
已完结
Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer
8天前
已完结
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment
15天前
已完结
精准医疗"时代从乳腺癌分子分型探讨抗体-药物偶联物的临床价值及最新研究进展
1个月前
已完结
Dato-DXd在乳腺癌治疗中的应用效果、安全性及耐药机制研究进展
1个月前
已完结
皖公网安备34019202002308
